Drug Profile
Merigolix - TiumBio
Alternative Names: HS-10518; NCE-403; SKI-2670; TU-2670Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator TiumBio
- Developer Daewon Pharmaceutical; Jiangsu Hansoh Pharmaceutical; TiumBio
- Class Antineoplastics; Small molecules
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis; Uterine leiomyoma
Most Recent Events
- 12 Apr 2024 Chemical structure information added
- 16 Jan 2024 Phase-I clinical trials in Endometriosis in China (PO), prior to January 2024 (TiumBio Pipeline, January 2024)
- 16 Jan 2024 Phase-II clinical trials in Uterine leiomyoma in South Korea (PO), prior to January 2024 (TiumBio Pipeline, January 2024)